Last edition
News about "BioAtla"
BioAtla Advances Phase 3 Oz-V Programme with Manufacturing-Ready SPV Structure
BioAtla, Inc., a global clinical-stage biotechnology company developing Conditionally Active Biologic (CAB) antibody therapies for solid tumours, has entered into a special purpose vehicle (SPV) transaction with GATC Health Corp. to advance its lead asset, ozuriftamab vedotin (Oz-V), into a phase 3 clinical trial for second-line and later OPSCC.
BioAtla | 04/01/2026 | By Darshana | 223
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy